Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| Prime Medicine, Inc.PRME · Entity 5281 | Director | June 05, 2026 | June 08, 2026 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
Prime Medicine, Inc.
Report date June 05, 2026 · Filed June 08, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $3.06 · Expires 2036-06-05 | Direct | 75,000 |
Reported balance
After 2026-06-05 transaction · row 1
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 1 · 2026-06-05 · Grant · Acquired 75,000 · Balance 75,000 F1: The shares subject to this option shall vest in full upon the earlier of (i) June 5, 2027 or (ii) the date of the next annual meeting of stockholders, subject to the Reporting Person's continuous service to the Issuer through such vesting date. |
Filing footnotes · ownership attribution and instrument terms
F1: The shares subject to this option shall vest in full upon the earlier of (i) June 5, 2027 or (ii) the date of the next annual meeting of stockholders, subject to the Reporting Person's continuous service to the Issuer through such vesting date.
Past disclosures · reporting ended (1)
No longer tracked through insider filings. These historical balances do not imply present ownership or a zero position.
Spark Therapeutics, Inc.
Report date December 17, 2019 · Filed December 17, 2019
Section 16 reporting ended · disclosed 2019-12-17. Current position is not established by this disclosure.
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 0 |
Reported balance
After 2019-12-17 transaction · row 1
1 source rowRow 1 · 2019-12-17 · Other · Disposed 355,215 · Balance 0 F1: Disposed of pursuant to the Agreement and Plan of Merger, dated February 22, 2019, by and between Spark Therapeutics, Inc. ("Spark"), Roche Holdings, Inc. ("Roche") and 022019 Merger Subsidiary, Inc. ("Merger Sub") (the "Merger Agreement" and the transactions contemplated thereby, the "Merger"), whereby Roche caused Merger Sub to conduct a tender offer for all of the issued and outstanding shares of common stock, par value $0.001 per share, of Spark, at a price of $114.50 per share. On December 17, 2019, Merger Sub irrevocably accepted for payment all shares that were validly tendered and not withdrawn. |
| Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $42.73 · Expires 2029-01-15 | Direct | 0 |
Reported balance
After 2019-12-17 transaction · row 2
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 2 · 2019-12-17 · Disposition to issuer · Disposed 98,000 · Balance 0 F2: Pursuant to the terms of the Merger Agreement, immediately prior to the effective time of the Merger, each outstanding Spark stock option, whether vested or unvested, was converted into the right to an amount in cash (less applicable tax withholdings) equal to the product of (a) the excess of $114.50 over the per share exercise price of such stock option and (b) the total number of shares of common stock subject to such stock option. |
| Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $50.55 · Expires 2028-01-17 | Direct | 0 |
Reported balance
After 2019-12-17 transaction · row 3
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 3 · 2019-12-17 · Disposition to issuer · Disposed 52,500 · Balance 0 F2: Pursuant to the terms of the Merger Agreement, immediately prior to the effective time of the Merger, each outstanding Spark stock option, whether vested or unvested, was converted into the right to an amount in cash (less applicable tax withholdings) equal to the product of (a) the excess of $114.50 over the per share exercise price of such stock option and (b) the total number of shares of common stock subject to such stock option. |
| Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $56.17 · Expires 2027-01-17 | Direct | 0 |
Reported balance
After 2019-12-17 transaction · row 4
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 4 · 2019-12-17 · Disposition to issuer · Disposed 70,000 · Balance 0 F2: Pursuant to the terms of the Merger Agreement, immediately prior to the effective time of the Merger, each outstanding Spark stock option, whether vested or unvested, was converted into the right to an amount in cash (less applicable tax withholdings) equal to the product of (a) the excess of $114.50 over the per share exercise price of such stock option and (b) the total number of shares of common stock subject to such stock option. |
| Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $40.44 · Expires 2026-01-04 | Direct | 0 |
Reported balance
After 2019-12-17 transaction · row 5
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 5 · 2019-12-17 · Disposition to issuer · Disposed 135,000 · Balance 0 F2: Pursuant to the terms of the Merger Agreement, immediately prior to the effective time of the Merger, each outstanding Spark stock option, whether vested or unvested, was converted into the right to an amount in cash (less applicable tax withholdings) equal to the product of (a) the excess of $114.50 over the per share exercise price of such stock option and (b) the total number of shares of common stock subject to such stock option. |
| Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $68.45 · Expires 2025-03-15 | Direct | 0 |
Reported balance
After 2019-12-17 transaction · row 6
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 6 · 2019-12-17 · Disposition to issuer · Disposed 125,000 · Balance 0 F2: Pursuant to the terms of the Merger Agreement, immediately prior to the effective time of the Merger, each outstanding Spark stock option, whether vested or unvested, was converted into the right to an amount in cash (less applicable tax withholdings) equal to the product of (a) the excess of $114.50 over the per share exercise price of such stock option and (b) the total number of shares of common stock subject to such stock option. |
| Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $3.45 · Expires 2024-07-01 | Direct | 0 |
Reported balance
After 2019-12-17 transaction · row 7
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 7 · 2019-12-17 · Disposition to issuer · Disposed 126,131 · Balance 0 F2: Pursuant to the terms of the Merger Agreement, immediately prior to the effective time of the Merger, each outstanding Spark stock option, whether vested or unvested, was converted into the right to an amount in cash (less applicable tax withholdings) equal to the product of (a) the excess of $114.50 over the per share exercise price of such stock option and (b) the total number of shares of common stock subject to such stock option. |
| Restricted Stock UnitsSEC Table II · derivative / convertible security · Conversion / exercise price $0.00 | Direct | 0 |
Reported balance
After 2019-12-17 transaction · row 8
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 8 · 2019-12-17 · Disposition to issuer · Disposed 49,250 · Balance 0 F3: Pursuant to the terms of the Merger Agreement, immediately prior to the effective time of the Merger, each outstanding Spark restricted stock unit, whether vested or unvested, was canceled and converted into the right to receive $114.50 in cash (less applicable tax withholdings). |
Filing footnotes · ownership attribution and instrument terms
F1: Disposed of pursuant to the Agreement and Plan of Merger, dated February 22, 2019, by and between Spark Therapeutics, Inc. ("Spark"), Roche Holdings, Inc. ("Roche") and 022019 Merger Subsidiary, Inc. ("Merger Sub") (the "Merger Agreement" and the transactions contemplated thereby, the "Merger"), whereby Roche caused Merger Sub to conduct a tender offer for all of the issued and outstanding shares of common stock, par value $0.001 per share, of Spark, at a price of $114.50 per share. On December 17, 2019, Merger Sub irrevocably accepted for payment all shares that were validly tendered and not withdrawn.
F2: Pursuant to the terms of the Merger Agreement, immediately prior to the effective time of the Merger, each outstanding Spark stock option, whether vested or unvested, was converted into the right to an amount in cash (less applicable tax withholdings) equal to the product of (a) the excess of $114.50 over the per share exercise price of such stock option and (b) the total number of shares of common stock subject to such stock option.
F3: Pursuant to the terms of the Merger Agreement, immediately prior to the effective time of the Merger, each outstanding Spark restricted stock unit, whether vested or unvested, was canceled and converted into the right to receive $114.50 in cash (less applicable tax withholdings).
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| August 02, 2017 Filed Aug 4, 2017 20:02 UTC | Spark Therapeutics, Inc. ONCE · Entity 153045 | Exercise / conversionCommon Stock | 28,650 | $3.45 | $98,842.50 |
DisclosureSEC source: 0001609351-17-000090 · wf-form4_150187693186983.xml · nonDerivative · entry 1 Marrazzo Jeffrey D · CIK 0001631262 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 258,650 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| July 05, 2017 Filed Jul 7, 2017 20:40 UTC | Spark Therapeutics, Inc. ONCE · Entity 153045 | Exercise / conversionStock Option (right to buy) · Derivative | 5,669 | $0.00 Strike: $3.45 | $0.00 |
DisclosureSEC source: 0001609351-17-000069 · wf-form4_149946000555109.xml · derivative · entry 3 Marrazzo Jeffrey D · CIK 0001631262 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 327,071 Underlying: Common Stock · 5,669 shares Expires 2024-07-01 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · derivative.exercise_date: This option was granted on July 2, 2014 and vests over four years, with 25% of the shares underlying the option vesting on May 24, 2015, and the remainder vesting quarterly thereafter. Read SEC document |
| July 05, 2017 Filed Jul 7, 2017 20:40 UTC | Spark Therapeutics, Inc. ONCE · Entity 153045 | SaleCommon Stock | 5,669 | $65.00 | $368,485.00 |
DisclosureSEC source: 0001609351-17-000069 · wf-form4_149946000555109.xml · nonDerivative · entry 2 Marrazzo Jeffrey D · CIK 0001631262 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 230,000 F1 · kind: The sale reported in the Form 4 was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on December 14, 2016. Read SEC document |
| July 05, 2017 Filed Jul 7, 2017 20:40 UTC | Spark Therapeutics, Inc. ONCE · Entity 153045 | Exercise / conversionCommon Stock | 5,669 | $3.45 | $19,558.05 |
DisclosureSEC source: 0001609351-17-000069 · wf-form4_149946000555109.xml · nonDerivative · entry 1 Marrazzo Jeffrey D · CIK 0001631262 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 235,669 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| June 21, 2017 Filed Jun 22, 2017 21:42 UTC | Spark Therapeutics, Inc. ONCE · Entity 153045 | Exercise / conversionStock Option (right to buy) · Derivative | 8,797 | $0.00 Strike: $3.45 | $0.00 |
DisclosureSEC source: 0001609351-17-000063 · wf-form4_149816773739664.xml · derivative · entry 6 Marrazzo Jeffrey D · CIK 0001631262 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 332,740 Underlying: Common Stock · 8,797 shares Expires 2024-07-01 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · derivative.exercise_date: This option was granted on July 2, 2014 and vests over four years, with 25% of the shares underlying the option vesting on May 24, 2015, and the remainder vesting quarterly thereafter. Read SEC document |
| June 21, 2017 Filed Jun 22, 2017 21:42 UTC | Spark Therapeutics, Inc. ONCE · Entity 153045 | SaleCommon Stock | 8,797 | $65.00 | $571,805.00 |
DisclosureSEC source: 0001609351-17-000063 · wf-form4_149816773739664.xml · nonDerivative · entry 4 Marrazzo Jeffrey D · CIK 0001631262 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 230,000 F1 · kind: The sale reported in the Form 4 was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on December 14, 2016. Read SEC document |
| June 21, 2017 Filed Jun 22, 2017 21:42 UTC | Spark Therapeutics, Inc. ONCE · Entity 153045 | Exercise / conversionCommon Stock | 8,797 | $3.45 | $30,349.65 |
DisclosureSEC source: 0001609351-17-000063 · wf-form4_149816773739664.xml · nonDerivative · entry 3 Marrazzo Jeffrey D · CIK 0001631262 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 238,797 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| June 20, 2017 Filed Jun 22, 2017 21:42 UTC | Spark Therapeutics, Inc. ONCE · Entity 153045 | Exercise / conversionStock Option (right to buy) · Derivative | 534 | $0.00 Strike: $3.45 | $0.00 |
DisclosureSEC source: 0001609351-17-000063 · wf-form4_149816773739664.xml · derivative · entry 5 Marrazzo Jeffrey D · CIK 0001631262 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 341,537 Underlying: Common Stock · 534 shares Expires 2024-07-01 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · derivative.exercise_date: This option was granted on July 2, 2014 and vests over four years, with 25% of the shares underlying the option vesting on May 24, 2015, and the remainder vesting quarterly thereafter. Read SEC document |
| June 20, 2017 Filed Jun 22, 2017 21:42 UTC | Spark Therapeutics, Inc. ONCE · Entity 153045 | SaleCommon Stock | 534 | $65.00 | $34,710.00 |
DisclosureSEC source: 0001609351-17-000063 · wf-form4_149816773739664.xml · nonDerivative · entry 2 Marrazzo Jeffrey D · CIK 0001631262 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 230,000 F1 · kind: The sale reported in the Form 4 was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on December 14, 2016. Read SEC document |
| June 20, 2017 Filed Jun 22, 2017 21:42 UTC | Spark Therapeutics, Inc. ONCE · Entity 153045 | Exercise / conversionCommon Stock | 534 | $3.45 | $1,842.30 |
DisclosureSEC source: 0001609351-17-000063 · wf-form4_149816773739664.xml · nonDerivative · entry 1 Marrazzo Jeffrey D · CIK 0001631262 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 230,534 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| January 18, 2017 Filed Jan 20, 2017 21:05 UTC | Spark Therapeutics, Inc. ONCE · Entity 153045 | GrantRestricted Stock Units · Derivative | 20,000 | $0.00 | $0.00 |
DisclosureSEC source: 0001609351-17-000009 · wf-form4_148494629153443.xml · derivative · entry 2 Marrazzo Jeffrey D · CIK 0001631262 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 40,000 Underlying: Common Stock · 20,000 shares Expires not disclosed F2 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one share of Spark Therapeutics common stock. F3 · derivative.exercise_date: The restricted stock units vest in four equal annual installments beginning January 18, 2018. Vested shares will be delivered to the reporting person annually on the vesting date. F3 · derivative.expiration_date: The restricted stock units vest in four equal annual installments beginning January 18, 2018. Vested shares will be delivered to the reporting person annually on the vesting date. Read SEC document |
| January 18, 2017 Filed Jan 20, 2017 21:05 UTC | Spark Therapeutics, Inc. ONCE · Entity 153045 | GrantEmployee Stock Option (right to buy) · Derivative | 70,000 | $0.00 Strike: $56.17 | $0.00 |
DisclosureSEC source: 0001609351-17-000009 · wf-form4_148494629153443.xml · derivative · entry 1 Marrazzo Jeffrey D · CIK 0001631262 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 70,000 Underlying: Common Stock · 70,000 shares Expires 2027-01-17 F1 · derivative.exercise_date: 25% vests January 18, 2018 and the remainder vests in equal annual installments over the following three years. Read SEC document |
| October 17, 2016 Filed Oct 19, 2016 21:32 UTC | Spark Therapeutics, Inc. ONCE · Entity 153045 | Exercise / conversionStock Option (right to buy) · Derivative | 5,000 | $0.00 Strike: $3.45 | $0.00 |
DisclosureSEC source: 0001609351-16-000103 · wf-form4_147691275773734.xml · derivative · entry 5 Marrazzo Jeffrey D · CIK 0001631262 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 342,071 Underlying: Common Stock · 5,000 shares Expires 2024-07-01 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F5 · derivative.exercise_date: This option was granted on July 2, 2014 and vests over four years, with 25% of the shares underlying the option vesting on May 24, 2015, and the remainder vesting quarterly thereafter. Read SEC document |
| October 17, 2016 Filed Oct 19, 2016 21:32 UTC | Spark Therapeutics, Inc. ONCE · Entity 153045 | SaleCommon Stock | 300 | $55.71 | $16,713.00 |
DisclosureSEC source: 0001609351-16-000103 · wf-form4_147691275773734.xml · nonDerivative · entry 4 Marrazzo Jeffrey D · CIK 0001631262 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 230,000 F1 · kind: The sale reported in the Form 4 was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on October 16, 2015. F4 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $55.62 to $55.85, inclusive. The reporting person undertakes to provide to Spark Therapeutics, Inc., any security holder of Spark Therapeutics, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in footnote (4) to this Form 4. Read SEC document |
| October 17, 2016 Filed Oct 19, 2016 21:32 UTC | Spark Therapeutics, Inc. ONCE · Entity 153045 | SaleCommon Stock | 2,300 | $55.11 | $126,753.00 |
DisclosureSEC source: 0001609351-16-000103 · wf-form4_147691275773734.xml · nonDerivative · entry 3 Marrazzo Jeffrey D · CIK 0001631262 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 230,300 F1 · kind: The sale reported in the Form 4 was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on October 16, 2015. F3 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $54.61 to $55.58, inclusive. The reporting person undertakes to provide to Spark Therapeutics, Inc., any security holder of Spark Therapeutics, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in footnote (3) to this Form 4. Read SEC document |
| October 17, 2016 Filed Oct 19, 2016 21:32 UTC | Spark Therapeutics, Inc. ONCE · Entity 153045 | SaleCommon Stock | 2,400 | $54.10 | $129,840.00 |
DisclosureSEC source: 0001609351-16-000103 · wf-form4_147691275773734.xml · nonDerivative · entry 2 Marrazzo Jeffrey D · CIK 0001631262 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 232,600 F1 · kind: The sale reported in the Form 4 was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on October 16, 2015. F2 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $53.59 to $54.57, inclusive. The reporting person undertakes to provide to Spark Therapeutics, Inc., any security holder of Spark Therapeutics, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in footnote (2) to this Form 4. Read SEC document |
| October 17, 2016 Filed Oct 19, 2016 21:32 UTC | Spark Therapeutics, Inc. ONCE · Entity 153045 | Exercise / conversionCommon Stock | 5,000 | $3.45 | $17,250.00 |
DisclosureSEC source: 0001609351-16-000103 · wf-form4_147691275773734.xml · nonDerivative · entry 1 Marrazzo Jeffrey D · CIK 0001631262 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 235,000 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| September 16, 2016 Filed Sep 19, 2016 20:36 UTC | Spark Therapeutics, Inc. ONCE · Entity 153045 | Exercise / conversionStock Option (right to buy) · Derivative | 10,000 | $0.00 Strike: $3.45 | $0.00 |
DisclosureSEC source: 0001609351-16-000098 · wf-form4_147431739613625.xml · derivative · entry 5 Marrazzo Jeffrey D · CIK 0001631262 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 347,071 Underlying: Common Stock · 10,000 shares Expires 2024-07-01 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F5 · derivative.exercise_date: This option was granted on July 2, 2014 and vests over four years, with 25% of the shares underlying the option vesting on May 24, 2015, and the remainder vesting quarterly thereafter. Read SEC document |
| September 16, 2016 Filed Sep 19, 2016 20:36 UTC | Spark Therapeutics, Inc. ONCE · Entity 153045 | SaleCommon Stock | 3,810 | $63.54 | $242,087.40 |
DisclosureSEC source: 0001609351-16-000098 · wf-form4_147431739613625.xml · nonDerivative · entry 4 Marrazzo Jeffrey D · CIK 0001631262 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 230,000 F1 · kind: The sale reported in the Form 4 was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on October 16, 2015. F4 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $63.23 to $63.92, inclusive. The reporting person undertakes to provide to Spark Therapeutics, Inc., any security holder of Spark Therapeutics, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in footnote (4) to this Form 4. Read SEC document |
| September 16, 2016 Filed Sep 19, 2016 20:36 UTC | Spark Therapeutics, Inc. ONCE · Entity 153045 | SaleCommon Stock | 3,369 | $62.53 | $210,663.57 |
DisclosureSEC source: 0001609351-16-000098 · wf-form4_147431739613625.xml · nonDerivative · entry 3 Marrazzo Jeffrey D · CIK 0001631262 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 233,810 F1 · kind: The sale reported in the Form 4 was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on October 16, 2015. F3 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $62.22 to $63.14, inclusive. The reporting person undertakes to provide to Spark Therapeutics, Inc., any security holder of Spark Therapeutics, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in footnote (3) to this Form 4. Read SEC document |
| September 16, 2016 Filed Sep 19, 2016 20:36 UTC | Spark Therapeutics, Inc. ONCE · Entity 153045 | SaleCommon Stock | 2,821 | $61.71 | $174,083.91 |
DisclosureSEC source: 0001609351-16-000098 · wf-form4_147431739613625.xml · nonDerivative · entry 2 Marrazzo Jeffrey D · CIK 0001631262 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 237,179 F1 · kind: The sale reported in the Form 4 was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on October 16, 2015. F2 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $61.21 to $62.20, inclusive. The reporting person undertakes to provide to Spark Therapeutics, Inc., any security holder of Spark Therapeutics, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in footnote (2) to this Form 4. Read SEC document |
| September 16, 2016 Filed Sep 19, 2016 20:36 UTC | Spark Therapeutics, Inc. ONCE · Entity 153045 | Exercise / conversionCommon Stock | 10,000 | $3.45 | $34,500.00 |
DisclosureSEC source: 0001609351-16-000098 · wf-form4_147431739613625.xml · nonDerivative · entry 1 Marrazzo Jeffrey D · CIK 0001631262 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 240,000 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.